GHK-Cu (glycyl-L-histidyl-L-lysine copper peptide) is a naturally occurring tripeptide-copper complex found in human plasma. It is not FDA-approved as a drug in either its topical or injectable form. TruVera provides GHK-Cu through licensed 503A compounding pharmacies — available only with a valid prescription from a licensed clinician following a thorough medical intake. Many cosmetic products also contain GHK-Cu as an ingredient, but compounded pharmaceutical-grade formulations require a prescription and are distinct from over-the-counter cosmetics.

GHK-Cu operates through several converging pathways. It activates TGF-beta signaling, prompting fibroblasts to synthesize new collagen (types I and III), elastin, and glycosaminoglycans — the proteins responsible for skin firmness and elasticity. It modulates matrix metalloproteinases to remodel damaged extracellular matrix more efficiently. It also activates the Nrf2 antioxidant pathway, upregulating protective enzymes that neutralize free radicals and reduce oxidative stress at the cellular level. Together these mechanisms support both structural skin renewal and protection against ongoing environmental damage.

GHK-Cu can be compounded in topical cream or serum form (applied directly to target skin areas) or as a subcutaneous injectable (for more systemic tissue effects). Your clinician will assess your skin goals, current health status, and medical history to determine the most appropriate formulation, dose, and route of administration. Some protocols combine topical and injectable approaches for comprehensive results.

Most patients begin to notice improvements in skin texture, hydration, and luminosity within 6–8 weeks of consistent use. More significant changes to firmness, fine lines, and skin thickness typically become apparent at the 10–12 week mark as new collagen is deposited and matures. Full remodeling benefits continue to develop over several months. Your clinician will assess your response at scheduled check-ins and adjust your protocol as needed.

GHK-Cu is generally well tolerated. Topical formulations may cause mild transient redness or a warm sensation when first introduced — this typically resolves within the first week or two as skin adjusts. Injectable formulations may produce temporary injection-site reactions including minor bruising, swelling, or redness. Systemic side effects are uncommon at therapeutic doses. Patients with known copper metabolism disorders (such as Wilson's disease) should not use GHK-Cu. Your clinician will review your complete health history and medications before prescribing.

Yes. You can pause or cancel at any time through your TruVera patient portal — no phone calls, no cancellation fees. If you have questions about your protocol or want to explore adjustments before canceling, your care team is always available to help.